Navigation Links
Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
Date:7/31/2008

DUSSELDORF, Germany, August 1 /PRNewswire-FirstCall/ --

- Further Focus on Pharma & Life Science

Gerresheimer AG is to discontinue its business in technical plastic systems. The business segment, which primarily manufactures system components for suppliers to the automobile industry, is not part of the core business of pharma & life science. For this purpose the sale process has been started through an international invitation for bids.

"Through the sale of the technical plastics business we are, as previously announced, continuing our focus on the core business of pharma & life science, "says Dr. Axel Herberg, CEO of Gerresheimer AG.

In the segment of technical plastic systems, Gerresheimer employs 550 people at locations in Germany, the Czech Republic and Mexico as well as through joint ventures in Italy and Bulgaria, manufacturing system components for suppliers to the automobile industry. The main product focus is on vehicle electrics, powertrain and chassis as well as interior. Sales of around EUR 70m are expected for this segment in the financial year 2008.

Gerresheimer acquired the technical plastics business in 2007 as part of the Wilden Group. While the Wilden Group's business in medical plastic systems has today been firmly integrated in the Gerresheimer Group's portfolio, the technical plastics segment does not belong to Gerresheimer's core business in pharma & life science. Through the sale, portfolio rationalisation in the Plastic Systems Division will be completed.

In June this year, the Dusseldorf company already sold off its consumer healthcare business, which also did not fit in with its core business.

About Gerresheimer

Gerresheimer employs more than 10,300 people in 40 locations in Europe, America and Asia. In the financial year 2007, worldwide sales totalled EUR 958m. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterised by high technical and regulatory barriers.

Contact Press

Burkhard Lingenberg

Director Corporate PR & Marketing

Telephone: +49-211-6181-250

Telefax: +49-211-6181-241

E-mail: b.lingenberg@gerresheimer.com

Contact Investor Relations

Anke Linnartz

Director Corporate Investor

Director Corporate Investor Relations

Telephone: +49-211-6181-314

Telefax: +49-211-6181-121

E-mail: a.linnartz@gerresheimer.com


'/>"/>
SOURCE Gerresheimer AG
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Gerresheimer Further Increases its Sales and Earnings Power
2. Gerresheimer Discontinues Marginal Operations
3. Moodys Raises Rating for Gerresheimer
4. Gerresheimer: Record Year in 2007 and Positive Outlook for 2008
5. 2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
6. Yves Lionel Assant is New Chairman of Gerresheimers Supervisory Board
7. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
10. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , ... February 10, 2016 , ... ... medicine, has announced a new agreement with Singapore-based Global Stem Cells Network (GSCN) ... the Philippines, Thailand and Singapore in the latest adipose and bone marrow therapies. ...
(Date:2/9/2016)... 9, 2016  Regenicin, Inc. (OTC Bulletin Board: ... the development and commercialization of regenerative cell therapies ... organs, recently reported the Company,s operating results for ... 2016. Lonza America , Inc. (the ... year in the process of consummating an agreement ...
(Date:2/9/2016)... King of Prussia, PA (PRWEB) , ... February 09, 2016 , ... ... Director, Business Development, Europe. Based in Paris, he will focus on acquiring new ... needs are being met. , “Fred brings to our European clients ...
(Date:2/9/2016)... 9, 2016  DNAtrix, a clinical stage, ... announced that its lead product, DNX-2401, has ... an orphan medicinal product for the treatment ... glioma, strikes approximately 25,000 people a year ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
Breaking Biology Technology:
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
(Date:2/1/2016)... Canada , February 1, 2016 ... technological advancements to drive global touchfree intuitive gesture control ... --> Rising sales of consumer electronics coupled ... gesture control market size through ... consumer electronics coupled with new technological advancements to drive ...
(Date:2/1/2016)... wallet ( www.wocketwallet.com ) announces the launch of a new video featuring ... Las Vegas , where Joey appeared at the Wocket booth ... , where Joey appeared at the Wocket booth to meet and ... at the Consumer Electronics Show (CES2016) in Las Vegas ... fans. --> --> The video ...
Breaking Biology News(10 mins):